These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15163503)

  • 21. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting epidermal Langerhans cells by epidermal powder immunization.
    Chen D; Payne LG
    Cell Res; 2002 Jun; 12(2):97-104. PubMed ID: 12118944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.
    Chen D; Periwal SB; Larrivee K; Zuleger C; Erickson CA; Endres RL; Payne LG
    J Virol; 2001 Sep; 75(17):7956-65. PubMed ID: 11483740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
    Cox RJ; Hovden AO; Brokstad KA; Szyszko E; Madhun AS; Haaheim LR
    Vaccine; 2006 Nov; 24(44-46):6585-7. PubMed ID: 16839650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
    Lambkin R; Oxford JS; Bossuyt S; Mann A; Metcalfe IC; Herzog C; Viret JF; Glück R
    Vaccine; 2004 Oct; 22(31-32):4390-6. PubMed ID: 15474733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model.
    Babiuk S; Skowronski DM; De Serres G; HayGlass K; Brunham RC; Babiuk L
    J Med Virol; 2004 Jan; 72(1):138-42. PubMed ID: 14635022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines.
    Ghendon Y; Markushin S; Krivtsov G; Akopova I
    Arch Virol; 2008; 153(5):831-7. PubMed ID: 18297235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza.
    Williman J; Young S; Buchan G; Slobbe L; Wilson M; Pang P; Austyn J; Preston S; Baird M
    Vaccine; 2008 Sep; 26(40):5153-8. PubMed ID: 18456374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
    Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
    Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.
    Zeman AM; Holmes TH; Stamatis S; Tu W; He XS; Bouvier N; Kemble G; Greenberg HB; Lewis DB; Arvin AM; Dekker CL
    Pediatr Infect Dis J; 2007 Feb; 26(2):107-15. PubMed ID: 17259871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection.
    Quan FS; Compans RW; Cho YK; Kang SM
    Vaccine; 2007 Jan; 25(2):272-82. PubMed ID: 16945454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
    Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR
    Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.